The treatment of hyperhomocysteinemia

Area of Science:

• Biochemistry
• Cardiovascular Science
• Neurology

Background:

• Homocysteine's reactivity contributes to oxidant stress and cellular toxicity.
• Hyperhomocysteinemia is an established risk factor for cardiovascular, cerebrovascular, and cognitive disorders.
• B-vitamin therapy effectively reduces homocysteine levels.

Purpose of the Study:

• To evaluate the clinical utility of homocysteine reduction in specific patient populations.
• To address limitations of previous trials that focused on mildly elevated homocysteine levels.

Main Methods:

• Review of epidemiological data and randomized controlled trials.
• Analysis of clinical scenarios where homocysteine reduction may be beneficial.

Main Results:

• Despite B-vitamin therapy reducing homocysteine, clinical trial outcomes have often been disappointing.
• Previous trials typically included patients with only mild hyperhomocysteinemia.
• Effectiveness in primary prevention or severe hyperhomocysteinemia remains underexplored.

Conclusions:

• Current evidence does not fully support widespread homocysteine monitoring for all patients.
• Further research is needed to identify patient subgroups (e.g., primary prevention, severe hyperhomocysteinemia) who may benefit from homocysteine reduction therapy.